Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL

Video

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Andre Goy, MD, Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service, Chairman & Chief Physician Officer - John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology - Hackensack Meridian School of Medicine, Professor of Medicine – Georgetown University, Hackensack, NJ, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma (MCL).

In July 2020, the FDA approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus) to treat patients with relapsed/refractory MCL. The regulatory decision was based on findings from the phase 2 ZUMA-2 trial, in which a single infusion of the CAR T-cell product elicited an 87% objective response rate and a 62% complete response (CR) rate in this patient population.

The next steps with brexucabtagene autoleucel, as well as CAR T-cell therapy overall, is to improve responses for patients who do not achieve a CR, says Goy. Although the field is developing a greater understanding of how to mitigate the toxicities associated with CAR T-cell therapy, improvements in outcomes for patients with MCL, an aggressive lymphoma subtype, are still needed, Goy explains. Moreover, the concept of heavily pretreated patients and T-cell fitness as a mechanism that limits T-cell amplification could shed light on future research efforts, Goy says. Evaluating CAR T-cell therapy in a larger population of high-risk patients could highlight the widespread effect of this therapeutic modality in this setting, concludes Goy.

Recent Videos
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
© 2025 MJH Life Sciences

All rights reserved.